However, intragroup analysis revealed that in vitro treatment of B cells with Resiquimod significantly decreased the expression of mTOR and HIF-1α genes in both CLL and normal groups. This evidence concerns the gene HIF1A and B-cell chronic lymphocytic leukemia.